During the November election, Oregon voters approved a measure allowing licensed centers to provide psilocybin, the substance found in “magic mushrooms,” to help treat people experiencing a range of mental health issues.

While the world waited breathlessly this fall for anything resembling definitive results from the Nov. 3 presidential election, one early winner seemed clear: drugs.

Psychedelic Stock Watch connects the dots regarding Mind Cure’s clinic launch and latest product development news.

Cybin Corp updates investors on its IP development

Numinus announces a product development agreement with Optimi Health Corp.

Vancouver, British Columbia–(Newsfile Corp. – January 4, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC (“Heading Health”), a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders.

PALM BEACH, Fla., Jan. 6, 2021 /PRNewswire/ — In the few places where cannabis is legal, it can be incredibly lucrative. In 2019, the nascent worldwide cannabis sector pumped out approximately $15 billion in sales.

Oakland, California–(Newsfile Corp. – January 4, 2021) – OTC:MINE signs a Joint Venture letter of intent with Lazurus Holistic to serve as psilocybin experts to grow and develop a unique strain of mushrooms specific to Jamaica.

ATLANTA, Jan. 04, 2021 (GLOBE NEWSWIRE) — 2020 was a banner year for investors in psychedelic companies as investors in Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), 20/20 Global, Inc. (OTC: TWGL), Compass Pathways (NASDAQ: CMPS), and Numinus Wellness Inc. (OTC: LKYSF) saw their money triple and even quadruple.